Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology

Gastroenterology. 2023 Nov;165(5):1308-1310. doi: 10.1053/j.gastro.2023.04.014. Epub 2023 Apr 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Bevacizumab / therapeutic use
  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Liver Neoplasms* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / diagnosis
  • Non-alcoholic Fatty Liver Disease* / drug therapy

Substances

  • atezolizumab
  • Bevacizumab
  • Antibodies, Monoclonal, Humanized